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Abstract
Background and aims: Iron deficiency anemia (IDA) is a common problem in patients with Inflamma-
tory Bowel Disease (IBD) and has a significant negative impact on quality of life. The aim was to com-
pare the clinical efficacy of intravenous (IV) versus oral (PO) iron replacement in adult IBD with iron
deficiency anemia (IDA).
Methods: A systematic search for randomized controlled trials comparing the efficacy of IV ver-
sus PO iron therapy in the treatment of IDA in adult IBD patients. The primary outcome was the
mean change in the hemoglobin at the end of study and secondary outcomes include mean
change in ferritin, clinical disease activity index, quality of life score and the adverse reaction
rate.
Results: The search strategy identified 757 articles while only three industry-funded articles
met the inclusion criteria for systematic review and meta-analysis. The total sample size was
333 patients with 203 patients receiving IV therapy. IV route was associated with a 6.8 g/L higher
mean hemoglobin increment and 110 μg/L higher mean ferritin increment. The IBD activity
index and Quality of Life scores were comparable between the two treatment groups. More ad-
verse events were reported in the oral treatment group with the odds for discontinuation being
6.2 (CI 2.2, 17.1).at any conference.
f Gastroenterology, Zeidler Ledcor Building, University of Alberta, Edmonton AB, Canada T6G 2X8.
9865.
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268 T.W. Lee et al.Conclusions: Intravenous iron treatment is better tolerated and more effective than oral iron
treatment in improving ferritin. The higher hemoglobin gain with the IV route was small and
of uncertain clinical significance. The combined sample size of the included studies was small
and further clinical trials are required.
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bowel disease (IBD) diagnosis has been reported to be as high
as 75% with iron deficiency being the most common.1,2 Re-
cent Scandinavian data indicated the prevalence of iron de-
ficiency anemia (IDA) at 20% and 30% had isolated iron
deficiency (without anemia). After treatment is stopped,
IDA normally recurs after 10 months and iron deficiency re-
curs about 19 months after treatment.3,4 IDA can be associ-
ated with reduced quality of life with complaints including
fatigue, concentration difficulties and slower cognitive re-
sponse.5,6 IDA has traditionally been treated with oral iron
supplements, however, concerns regarding its variable ab-
sorption in patients with IBD7and the possibility that oral
(PO) iron could exacerbate IBD has led to an increase in the
use of intravenous (IV) iron. Animal models have suggested
that PO iron therapy might exacerbate IBD through oxidative
radicals mediated mucosal injury8-10or by alterations in the
luminal microbiota.8,11 Moreover, animal models have dem-
onstrated that oxidative radicals may promote or upregulate
carcinogenic pathways as evidenced by a significantly higher
dysplasia rate in the colonic mucosa of mice given PO iron re-
placement.12-14 It is unclear whether these animal data have
any clinical consequences for the management of human IBD
patients with IDA. Thus far, one human study demonstrated
PO iron replacement therapy in patients with Crohn's disease(CD) reduces plasma antioxidants levels (such as cysteine
and glutathione) and increases CD activity.15 Another disad-
vantage of PO iron supplementation is the potential for side
effects such as nausea, abdominal cramping or pain and al-
tered bowel habits. Intolerance to oral iron therapy leading
to discontinuation has been reported to be as high as
20%.16,17
The advantage of using IV iron is that it bypasses the need
for gastrointestinal absorption, which is known to be vari-
able in IBD patients. Moreover, adherence with daily medi-
cation is less of an issue with IV iron as total iron
replacement can be achieved with 1–2 doses of low molecu-
lar weight Dextran or iron carboxymaltose infusions or more
frequent infusions3,4 if iron sucrose is used. The total dose of
iron given is determined by the degree of anemia and the
patient's body weight. However, there had been concerns
with the safety profile of IV iron infusion, especially with
the high molecular weight Dextran formulation which has
been reported to have an increased risk of anaphylaxis.
More recent formulations such as iron sucrose, low molecu-
lar weight iron dextran and iron carboxymaltose appear to
have a better safety profile2,18–20 Despite the improved
safety profile, IV iron infusions add additional costs to the
health care system which limit its widespread use.
Despite the fact that a few reviews have been published
on this topic2,21–23 including two qualitative systematic re-
views,4,24 confusion still exists as to what is the best way
to treat IDA in patients with IBD. The general awareness of
269Meta-analysis of iron replacement therapy in IBD patients with IDAthe management options for IDA in patients with IBD is sub-
optimal among some gastroenterologists.22 Some authors
propose that the route of iron replacement therapy should
depend on the degree of anemia. For example, it has been
suggested that IV replacement should be considered in pa-
tients with hemoglobin (HB) less than 100 g/L and those
with HBN100 g/L receive PO iron replacement.23
Several reviews have been written about this topic.1,2,4 A
problem with the existing reviews is that studies which used
concurrent Erythropoiesis-Stimulating Agents (ESA) in the
treatment of IDA in IBD are included..24,25 ESA is used in pa-
tients whose anemia is refractory to intravenous iron thera-
py and it is not a first line treatment.24 Moreover recent
studies in hemodialysis patients using ESA in the treatment
of anemia of chronic disease have raised concerns regarding
the association between the rapidity of HB improvement and
adverse cardiac outcomes26 Therefore caution is needed
with the addition of erythropoietin to the iron supplementa-
tion treatment of IBD patients with IDA and its use has been
reserved for patients not responding to adequate amounts of
intravenous iron replacement.
As more recent clinical trials have been published, the
objective of this systematic review and meta-analysis is to
compare the efficacy of IV versus PO iron replacement in
the treatment of IDA in patients with IBD. The primary out-
come measure was the mean change in HB and the secondary
outcome measures included the mean change in ferritin,
clinical disease activity indices, quality of life scores and ad-
verse reaction rate.
2. Materials and methods
2.1. Search methods
A systematic search of the following databases was per-
formed in January 2010. MEDLINE (1950 to February 2010,
Ovid interface), EMBASE (1980 to 2010 Week 04, Ovid inter-
face), Web of Science (2000–January 2010), Cochrane Data-
base of Systematic Reviews, Cochrane Central Register of
Controlled Trials (1991–January 2010), ClinicalTrials.gov
(2000–January 2010) and Database Abstracts of Reviews of
Effectiveness (1991–January 2010) was performed. MeSH
subject headings and text-words used include inflammatory
bowel disease, Crohn's disease, Crohn's colitis, ulcerative co-
litis, anemia, iron deficiency, ferric or ferrous compounds
and administration and dosage, adverse effects, deficiency,
therapeutic use. Abstracts from the American Gastroenter-
ology meeting — Digestive Disease Week (2004–2011) and
the European Gastroenterology meeting — United European
Gastroenterology Week (2004–2010) were hand searched
for additional publication. This search strategy was updated
in January 2011 followed by review of 2011 DDW abstracts
performed in June 2011.
2.2. Selection criteria
Randomized controlled clinical trials comparing the efficacy
of IV versus PO iron replacement therapy in adult IBD pa-
tients with IDA were included. Anemia was defined as
HBb120 g/L for females and HBb130 g/L for males.27 Iron
deficiency was defined as a serum ferritinb30μg/L orsaturationb20% if C Reactive Protein (CRP) was raised.28-30
Studies with concurrent use of erythropoietin and those pub-
lished in non-English or that employed a cross over study de-
sign were excluded. Cross-over study design was excluded
because the assumptions made in crossover study design
are that symptoms would return to baseline during the wash-
out period and the disease state is constant overtime.31 The
measured HB and ferritin improvement at the end of the sec-
ond period of intervention is likely influenced by the treat-
ment given during the first period. Therefore the crossover
design is not appropriate in IDA patients undergoing treat-
ment for IDA.
One author (TL) searched the database and screened the
retrieved citations by examining the abstracts. Abstracts
that met the broad inclusion criteria were selected for fur-
ther review. By following a pre-determined inclusion and ex-
clusion form, two reviewers (TL and MRK) independently
graded the abstracts as relevant (meeting all of the pre-de-
termined inclusion criteria), possibly relevant (meeting
some, but not all of the inclusion criteria), unclear or
rejected (failure to meet any of the inclusion criteria). Fi-
nally, both reviewers independently reviewed the full text
of all studies which, based on the data in the abstract,
were considered as relevant or possibly relevant. The final
decision regarding eligibility was reached by consensus and
any disagreement was resolved through discussion.2.3. Outcome measures
The primary outcome measure was the mean difference in
HB at the end of study compared to baseline. Secondary out-
comes included the mean difference in ferritin, the quality
of life (QoL) score using Short Form-36 questionnaire, in-
flammatory bowel disease activity indices such as Colitis Ac-
tivity Index (CAI) for ulcerative colitis and Crohn's Disease
Activity Index (CDAI) for CD and the adverse event rate.
Study authors were contacted to help with data clarification
where needed.2.4. Data extraction
Both reviewers independently extracted the data using a prede-
termined data extraction form. In studies where the outcome
measures were reported as medians, they were accepted as
means for the purpose of analysis. The inter-quartile Range
(IQR) was converted to an estimated standard deviation (SD)
using the formula ‘IQR/1.35’ and the range was converted to
an estimated standard deviation using the formula ‘range/4’32
The study by Kulnigg et al. expressed their results as median
and range; we successfully contacted the author and obtained
the results expressed as mean and standard deviation. The
mean end of study HB and ferritin in the study by Lindgren et
al. was presented graphically; therefore these values were di-
rectly taken from the graph. After attempts to contact the au-
thors of the study were unsuccessful to provide standard
deviations pertaining to the end of study HB and ferritin, it
was decided to use the standard deviation from Kulnigg's study
instead, as the two studies had similar methodology and study
population.33 TL and MRK assessed the methodological quality
of the studies independently based on the Cochrane
270 T.W. Lee et al.Collaboration's tool for assessing risk of bias form.34 A final de-
cision regarding the overall risk of bias was reached through
discussion.
2.5. Statistical analysis
Data was analyzed using Review Manager (RevMan) Version
5.1. [Copenhagen: The Nordic Cochrane Centre, the
Cochrane Collaboration, 2011]. The methodology and out-
come measures of the included studies were similar and
this allowed for pooling of results. All data were analyzed
on an intention-to-treat basis. A random effect model was
used as it provides a more conservative estimate of effect
size. Heterogeneity of the studies was assessed by I2. Publi-
cation bias was not assessed because of the small number of
included studies.
3. Results
The literature search identified 757 potential articles, 25 of
which were duplications. After initial review of the titles and
abstracts of 732 articles, 722 articles were excluded. Two
reviewers independently examined the full text of the 10
remaining articles resulting in exclusion of a further sevenFigure 1 Flow chart of liteof the retrieved articles (Fig. 1). Table 1 summarizes the
characteristics of the included studies and Table 2 summa-
rizes the reasons for excluding the 7 retrieved articles. The
three included studies have a total sample size of 333 pa-
tients, 203 of whom received IV iron replacement and 130
received PO iron replacement. An updated literature search
was performed in January 2011 and it did not yield any new
relevant clinical trial for inclusion in this review.
For the three studies, treatment allocation was done by
an external clinical trial company (Kulnigg study), by com-
puter generated random number table35 and by an Internet
based method.36 The allocation was not concealed in the
study by Schroder et al. as a computer generated random
number table was used to assign treatment group. There
was no blinding of participants or study staff members in
any study; however, study personnel were blinded to treat-
ment allocation in the Lindgren study.
There was incomplete outcome data reporting by Lindgren.
The end of treatment HB and ferritin was presented graphically
and no standard deviation was reported. The other two studies
presented all relevant outcome data, including the reasons for
screen failures. An external clinical trial company on behalf of
the sponsor in the Schroder and Kulnigg study performed the
data analysis. It is unclear from the manuscript if the authors
had full access to the collected data. It is also unclear whyrature search outcomes.
Table 1 Characteristics of the included studies.
Route N Baseline HB
(g/L)
Baseline ferritin
(μg/L)
EOT HB (g/L) EOT Ferritin
(μg/L)
mean total Fe
given (g)
Rx time
(week)
Schroder (2005)
(median, IQR)
F: Hb≤105 g/L
M: Hb≤115 g/L
TSAT≤20% or
Ferritin≤20 μg/L
PO 24 96(93–101) 8(5–39) 117 (111–129) 24 (11–49) Fe sulfate 4.2
(4.2–8.4)
6
IV 22 98(88–104) 12(5–37) 123 (109–126) 240 (186–427) Fe sucrose 1.4
(1.4–1.5)
6
Kulnigg (2008)
(median, range)
Hbb100 g/L
TSATb20% or
Ferritinb100 μg/L
PO 60 91(53–111) 6.5(1–383) 121 (65–174) 28.5(2–255) Fe sulfate 16.8 12
IV 136 87(50–115) 5 (1–399) 123 (60–159) 43.5(2–586) Fe
carboxymaltose
1.0
12
Lindgren (2009)
(mean±SD)
Hbb115 g/L
Ferritinb300 μg/L
Low TSAT
PO 46 103.8
±11.4
12.4±14.5 114 (using SD
from Kulnigg)
70 (using SD from
Kulnigg)
Fe sulfate 38.4
±20
20
IV 45 104.9±9.0 14.0±17.6 129 (using SD
from Kulnigg)
140 (using SD
from Kulnigg)
Fe sucrose 1.7
±0.3
20
TSAT: Transferrin saturation.
271Meta-analysis of iron replacement therapy in IBD patients with IDAKulnigg performed an interim analysis that resulted in the early
termination of the study. Based on the results from the interim
analysis the authors felt that sufficient statistical power was
achieved with a lower recruitment number. Therefore 52
fewer subjects were recruited. However, it is known that by
performing an interim analysis power may be overestimated.
This could potentially bias the results in favor of the intrave-
nous cohort. Finally, all three studies received financial spon-
sorship from the makers of IV iron and this could influence
the study outcomes and the decision regarding its publication.
The risk of bias from the study design and reporting point of
view is low for study by Schroder et al. Risk of bias was high
in the study by Kulnigg et al. because the reason for conducting
the interim analysis which led to early termination of the study
was unclear. The Risk of bias was also high in study by LindgrenTable 2 Characteristics of excluded studies.
Authors Year Journal Reason for exclusion
De Silva A.
et al.42
2003 Inflamm Bowel Dis Retrospective review,
Rosado B.
et al.43
2003 Gastroenterology DDW
Supplement
Retrospective review
Bodemar G.
et al.44
2004 Scand J Gastroenterol Retrospective review
De Silva A.
et al.17
2005 Aliment Pharmacol
Ther
Prospective study wit
Erichsen K.
et al.45
2005 Scand J Gastroenterol Prospective crossover
were treated with eit
sucrose. The treatmen
Iron study or Hb.
Katsanos K.
et al.46
2007 J Crohn's and Colitis Prospective iron infus
Gisbert J.P.
et al.23
2009 Inflamm Bowel Dis Prospective non-randoet al. because of incomplete data reporting. Moreover, having
pharmaceutical support and the possibility of limited access to
the study data were the basis for the overall assessment of a
high risk of bias.3.1. Primary endpoint
3.1.1. Mean change in hemoglobin
The range of the mean baseline HB was 89.7–103.8 g/L
for PO and 85.4–104.9 g/L for IV route and the range of the
mean end of study HB was 114–122.6 g/L for PO and
121.5–129 g/L for IV route (Table 1). Fig. 2 shows the forest
plot comparing the mean difference in the amount of HB im-
provement between IV and PO iron replacement fromoral iron therapy
of IV iron replacement therapy
of iron sucrose infusions
h oral iron therapy in IBD and non-IBD patients
design; sub-therapeutic dose of iron used how defined Patients
her iron fumarate 120 mg/day for 2 weeks or 600 mg IV iron
t duration was too short to enable measurable improvement in
ion study
mized study
Figure 2 The mean hemoglobin improvement between IV and PO routes of iron replacement therapy. CI: confidence interval.
272 T.W. Lee et al.baseline to end of study. The IV route was associated with a
greater improvement in the HB level than the PO route,
weighted mean difference in HB of 6.8 g/L (CI 0.9, 12.7).
This was statistically significant, p=0.02. There was signifi-
cant heterogeneity in the data with I2=80%. Heterogeneity
may be explained by the difference in the magnitude of HB
improvement (not the direction of treatment effect as all
studies showed improvement in favor of the IV route), the
duration of iron therapy and by follow up, which ranged
from 6 weeks to 20 weeks.3.2. Secondary endpoints
3.2.1. Mean change in the end of treatment ferritin
The baseline ferritin ranged from 5–383 μg/L for PO and
5–399 μg/L for the IV route (Table 1). Fig. 3 demonstrates
that IV iron replacement was superior in improving serum
ferritin level over PO iron replacement therapy: the mean
difference was 109.7 μg/L (CI 5.37, 214), p=0.04. There
was significant heterogeneity in the data with I2=99%. The
high I2 value observed reflects the difference in the magni-
tude but not the direction of ferritin improvement and this
is likely explained by differences in the duration of iron ther-
apy, which ranged from 6 weeks to 20 weeks.3.3. Adverse events/discontinuation
Table 3 describes the number and the nature of adverse
event that led to the discontinuation of iron replacement
therapy. Five out of 203 patients who received IV iron dis-
continued because of infusion related reactions,2 smallFigure 3 The mean difference in ferritin improvement between
interval.bowel hemorrhage,1 thrombophlebitis1 and thrombocytope-
nia.1 In comparison, 21 out of 130 patients in the PO iron re-
placement cohort discontinued iron replacement because of
gastrointestinal related side effects such as nausea, abdom-
inal pain and diarrhea. The odds ratio for discontinuing PO
iron treatment due to side effects compared to IV iron re-
placement was 6.2 (CI 2.21, 17.1) (Fig. 4). One patient
with a history of cardiac disease died of cardiac arrest
1 day after receiving iron carboxymaltose. The study authors
reported that ‘the event was considered unrelated to study
medication but related to the underlying cardiac disease.’37
3.4. Quality of life score
The studies by Schroder et al. and Kulnigg et al. reported an
increase in SF-36 score at the end of iron replacement ther-
apy irrespective of the route of replacement: 7–17 points in-
crement with IV iron and 8–17 points increment with PO iron
therapy. Both routes had a comparable improvement in SF
36 scores, the pooled mean difference between PO and IV
was 1.4 (CI −0.7, 3.5), which was not statistically significant
(Fig. 5). Lindgren et al. did not report on the effect of iron
therapy on quality of life.
3.5. Effects of treatment on disease activity
Schroder et al. did not demonstrate that there was a differ-
ence in change of disease activity when the two treatments
were compared. The median Crohn's Disease Activity Index
(CDAI) and the median Colitis Activity Index (CAI) were
lower at the end of the study compared to baseline in bothIV and PO routes of iron replacement therapy. CI: confidence
Table 3 Number of patients discontinued iron replacement therapy due to adverse event as reported by the study authors.
Studies Oral Intravenous
Number of
patients
discontinued
Schroder 5/24:
Gastrointestinal
side effects
2/22: rash,
nausea, edema;
thrombophlebitis
Kulnigg 5/60: flare of
ulcerative
colitis;
diarrhea;
asthma;
vomiting;
Stomach pain
2/136: (+1 death)
erythematous
rash; small bowel
hemorrhage
Lindgren 11/46:
Gastrointestinal
symptoms
1/45: (thrombocy
topenia)
273Meta-analysis of iron replacement therapy in IBD patients with IDAIV and PO iron replacement cohorts suggesting an improve-
ment in the clinical disease status. The changes in the medi-
an serum C-reactive protein levels at the end of study
compared to baseline were not statistically significant in
PO and IV group. Kulnigg et al. reported worsening of IBD
in two of the enrolled patients, one given PO and one IV
iron. Lindgren et al. did not comment on the effect of iron
therapy on IBD activity.
Both Schroder et al. and Kulnigg et al. listed the use of
concurrent medications including 5 amino-salicylates, im-
munomodulator such as azathioprine and corticosteroids.
During the 6 weeks of iron replacement therapy in the
study by Schroder et al., 25% of study participants had ongo-
ing active IBD as indicated by a persistently elevated disease
activity index. Successful prednisone tapering occurred in
75% of the study participants suggesting that clinically
these patients were improving. The study by Lindgren et
al. did not report on concurrent medication usage.4. Discussion
The comprehensive literature search for randomized con-
trolled trials comparing IV and PO iron therapy in iron defi-
cient anemic IBD patients only identified three studies,
which combined, included a total of 333 patients. There
was a small (6.8 g/L) but statistically significant differenceFigure 4 Odds ratio for discontinuation of iron replacement thera
Haenszel test.in favor of IV iron therapy in improving HB levels. Whether
this small difference is also clinically important is a matter
of debate as there is no agreement in the literature and
none of the studies a priori defined what amount of improve-
ment would be considered clinically important. For the out-
comes of serum ferritin levels and rate of adverse events IV
iron therapy clearly favored over PO therapy. There were no
differences in quality of life or IBD activity but the number
of patients available for these outcome measures is small.
This review has several methodological limitations. Most
importantly the total sample size was small. In addition
there were problems with data reporting, especially in the
study by Lindgren et al.,36 which did not report the standard
deviations for the end of study HB and ferritin levels. For
that reason these values were derived from the study by
Kulnigg et al., as they used the study design with similar in-
clusion criteria for patients.
Another limitation is that the duration of post iron re-
placement therapy follow up, varying from 8 to 20 weeks,
was relatively short. This makes it difficult to interpret if
the higher ferritin level is of clinical significance in terms
of a more durable HB improvement. Further clinical trials
with a longer duration of post infusion follow up are needed
to investigate this aspect. Some may also argue that the PO
dose of iron replacement therapy was low which would bias
the results in favor of IV therapy. In that regard the severity
of side effects of oral therapy is important as the withdrawalpy due to adverse events. CI, confidence interval; M–H, Mantel–
Figure 5 The mean change in SF-36 score between IV and PO routes of iron replacement therapy. CI: confidence interval.
274 T.W. Lee et al.rate was higher in patients receiving PO iron therapy. Higher
doses of PO iron may therefore affect patient compliance
further.
All three studies were analyzed on an intention to treat
basis. Using Cochrane Collaboration's risk of bias tool, the
overall risk of bias of the included studies was determined to
be high on multiple levels, including incomplete data report-
ing of the primary end point by Lindgren et al., an interim
analysis which led to early termination of study by Kulnigg et
al. and industry sponsorship in all three included studies.
The cost of using IV iron replacement therapy is also im-
portant. Direct costing components include the intravenous
iron itself. In Canada the cost of one vial of iron sucrose con-
taining 100 mg iron is $37.50, which is more expensive than
oral iron pills ($30/100 tablets of 300 mg iron sulfate). The
need for a medically supervised environment to give the iron
infusion ($238/infusion) and nursing time (4 h infusion time
+1 h preparation/observation time, @$52/h) also need to be
considered as well as the indirect costs related to travel
costs and possible time lost from work. The estimated total
cost for 900 mg iron sucrose infusion (three infusion of
300 mg iron sucrose) is CAD $1831.50 ($337.50 for iron su-
crose+$714 for infusion facility fee+$780 for nursing). In con-
trast, 100 tablets of 300 mg iron sulfate costs CAD $30. A
cost effectiveness study comparing two different intrave-
nous iron formulations (iron carboxymaltose versus iron su-
crose) has been done in anemic IBD patients38but none
comparing PO versus IV iron therapy for the treatment of
IDA in adult IBD patients. Compared to iron sucrose, treat-
ment with iron carboxymaltose would save CAD $475 (US
$460) per patient because total iron replacement can be
achieved with fewer iron carboxymaltose infusions.
Hepcidin has been shown to be an important regulator of
iron homeostasis.39 Chronic inflammation is associated with
an elevated serum hepcidin concentration, which resulted in
sequestration of iron stores in the reticuloendothelial system
and impaired intestinal iron absorption. In contrast, iron defi-
ciency anemia is associatedwith a low serum hepcidin concen-
tration, which enhances intestinal iron absorption and the
release of iron from the reticuloendothelial system.40,41 With
this in mind, oral iron therapy may not be as effective as intra-
venous iron therapy in the setting of a chronic active inflam-
matory state in the small bowel and colon.
Moreover, we were surprised with the small number of
published randomized controlled studies in this important
area. Despite the fact that so few studies met our inclusion
criteria, we decided to continue the review as we believe
it is important to highlight how limited the evidence from
the available literature is.
In conclusion, it is not surprising that IV iron replacement
therapy was superior in improving ferritin levels in IBDpatients with iron deficiency anemia, however the differ-
ence in the mean HB increment was small and the clinical
significance is uncertain. IV iron was associated with fewer
adverse events. Further studies are needed to examine this
important area to help establish the optimal management
of iron deficiency in these patients and to determine wheth-
er IV iron therapy is cost effective.
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